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Abstract 
The activity of N-hexanoyl-D-erythro-sphingosine, a C6-ceramide against angiogenesis 
was tested in vitro and in vivo. The effect of ceramide in inhibiting MCF-7 cancer cells was 
also determined. The aim of this study was to potentiate the effect of ceramide as an-
ti-angiogenic compound that can regulate tumor induced angiogenesis.   
C6-ceramide inhibited vascular endothelial growth factor (VEGF)-induced human um-
bilical  vein  endothelial  cells  (HUVEC)  tube  formation  in  a  dose-dependent  manner 
within 24 hours. Ceramide at concentrations between 12.5 and 25 μM inhibited the via-
bility of MCF-7 cells and reduced VEGF-induced cell migration in 24 hours. At 50 μM, 
ceramide induced MCF-7 cell death via autophagy as demonstrated by accumulation of 
MDC in ceramide-treated MCF-7 vacuoles. The expression of VEGF was reduced and the 
levels of cathepsin D in MCF-7 increased. In vivo, 50 μM ceramide caused a 40% reduc-
tion of new vessel formation in the CAM assay within 24 hours. Zebrafish exposed to 100 
- 400 μM ceramide had a distinct disruption of blood vessel development at 48 hours 
post-fertilization. Ceramide-exposed embryos also had primary motoneurons exhibiting 
abnormal axonal trajectories and ectopic branching. Ceramide induced cell-death was 
not detected in the zebrafish assay. Collectively, these data indicate that ceramide is a 
potent  anti-angiogenic  compound  and  that  the  mechanism  underlying  its  an-
ti-angiogenic capabilities does not rely upon the induction of apoptosis. 
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Introduction 
Ceramides  are  sphingolipid-derived,  bioactive 
second messengers.  These bioactive compounds are 
being actively studied as potential chemopreventive 
molecules because they are intimately involved in the 
regulation  of  cancer-cell  growth,  differentiation,  se-
nescence, and cell death (1, 2). Evidence indicates that 
primary and metastatic cancer cells contain less en-
dogenous  ceramides  compared  to  normal  mucosa 
from the same patient suggesting that ceramide bio-
synthesis processes may be disrupted in cancer cells 
(3). It has also been shown that radiation-resistant and 
multi-drug  resistant  tumor  cells  do  not  generate  or 
accumulate ceramides suggesting an alteration in the 
sphingolipid  pathway  (4).  As  a  proof  of  concept, 
treating cancer cells in vitro with exogenous ceramides 
invariably results in cycle arrest, senescence, differen-
tiation,  apoptosis  or  autophagy  (1,  5,  6).  Moreover, 
systemic delivery of exogenous ceramide to syngeneic 
Ivyspring  




Balb/C mice, a mammalian model of breast adeno-
carcinoma, significantly limits tumor growth (7). Pu-
tative mechanisms responsible for ceramide-induced 
apoptosis  of  mammary  cancer  cells  include  the  ac-
cumulation  of  ceramides  within  the  mitochondria 
which  leads  to  mitochondrial  dysfunction,  cyto-
chrome  c  release  and  caspase  activation, 
dephosphorylation  of  ceramide-activated  protein 
phosphatase,  control  of  calcium  homeostasis,  and 
activation of cathepsin D and protein kinase C ζ (1, 3, 
5, 7-9). We have recently demonstrated that ceramide 
methylaminoethylphosphonate  (CMAEPn),  a  natu-
rally occurring shingophospholipid inhibited the via-
bility  of  hormone-dependent  and  –independent 
breast  cancer  cells  by  inactivating  VEGF,  EGF,  and 
PI3K, which are some of the main signaling pathways 
associated with the progression of breast cancer (10). 
These  data  suggest  that  addition  of  exogenous 
ceramides  to  tumor  cells  provides  an  important 
mechanism  for  decreasing  tumor  cell  survival  and 
makes ceramide an attractive bioactive compound for 
cancer prevention and/or treatment.  
Vascular endothelial growth factor (VEGF) plays 
a major role in the process of vasculogenesis and an-
giogenesis (11). Aberrant expression of VEGF stimu-
lates angiogenesis in a strict dose-dependent manner 
in  diseases such  as  inflammation,  diabetes  mellitus 
complications,  cancer,  and  cardiovascular  diseases 
(11). VEGF mediates its effect on angiogenesis, under 
both  physiological  and  pathological  conditions,  by 
binding to its receptors KDR/Flk-1 (11). The growth 
factor is being evaluated as a target for pro- and an-
ti-angiogenesis therapy.  
The rapid anatomical development, transparen-
cy of the embryo, and rapid  circulatory system de-
velopment  similar  to  mammals  make  zebrafish  an 
attractive vertebrate model system for analysis of an-
giogenesis in vivo (12,  13).  Moreover,  recent  studies 
(14) have suggested that many molecules associated 
with axonal guidance of neurons within the nervous 
system, also regulate cell migration and apoptosis in 
normal  and  tumorigenic  tissues.  This  implies  that 
molecules or agents that can regulate axon guidance 
during vertebrate CNS development may also be able 
to  arrest  the  development  and  progression  of  can-
cerous tumors by inhibiting angiogenesis.  Signaling 
cascades  involved  in  nervous  system  development 
and angiogenesis share common signaling molecules 
participating  via  cross-talk  (15).  We  examined  the 
anti-angiogenic  activities  of  ceramide  in  vitro using 
human umbilical endothelial cells (HUVEC), cell mi-
gration  and  autophagy  using  MCF-7  breast  cancer 
cells. In vivo the activity of ceramide against angio-
genesis was evaluated using both the embryonic chick 
chorioallantoic membrane (CAM) assay and zebrafish 
model. We examined zebrafish embryogenesis to de-
termine whether angiogenesis and axon guidance are 
both influenced by ceramide exposure.   
Methods 
Cell culture and reagents 
Human  umbilical  vein  endothelial  cells 
(HUVEC)  were  obtained  from  Clonetics  (Cambrex, 
Rockland, ME) and grown as per the supplier’s in-
structions. Breast cancer (MCF-7) cells were obtained 
from  American  Type  Culture  Collection  (Rockville, 
MD) and grown as per ATCC’s instructions. The cells 
were passaged once per week at a split of 1:2 and fed 
once per week. These cells were grown in humidified 
incubator  containing  5%  CO2  at  37C. 
N-hexanoyl-D-erythro-sphingosine  (C6-Ceramide) 
was purchased from Avanti Polar Lipids (Alabaster, 
AL). All other reagents were of analytical grade.  
Cell proliferation and cathepsin D assays 
Confluent cultures of MCF-7 breast cancer cells 
were  seeded  on  96-well  plates  at  a  density  of  ap-
proximately 2x 104 cells/well in a total volume of 100 
µl. The cells were grown for 24 hours prior to expo-
sure.  MCF-7  cells  were  treated  by  addition  of  10 
ng/ml  of  17β-estradiol  prior  to  the  ceramide  expo-
sure. Ceramide was dissolved in dimethyl sulfoxide 
to  achieve  final  concentrations  of  0-100  μM  while 
making sure that DMSO concentration did not exceed 
0.1%. Untreated control cancer cells received less than 
0.1% of dimethyl sulfoxide (DMSO). All experiments 
were carried out in triplicates. Replicates of culture 
plates were prepared and incubated for 24 hours in a 
humidified incubator containing 5% CO2 at 37 ºC. At 
the  end  of  the  incubation  period,  cell  viability  and 
proliferation was  determined using  the CellTiter 96 
AQueous  One  solution  (Promega,  Madison,  WI).  The 
plate  was  read  at  490  nm  using a  Spectra Max Plus 
ELISA  plate  reader  (Molecular  Devices,  Sunnyvale, 
CA). Cell viability and proliferation were normalized 
to the levels in untreated control cells to determine the 
percentage of viable cells. Cathepsin D levels in the 
supernatants  were  analyzed using  a  commercial  kit 
(EMD Biosciences, Inc., San Diego, CA). 
Immuno-precipitation and western blot analysis of 
PI3K/AKT signaling 
MCF-7  cells  were  plated  in  6-well  dishes  and 
treated with the 50 μmol/L of ceramide, for 24 hours. 
After the treatment, the supernatants were removed 
and the cells were washed with ice cold phosphate 
buffered saline (PBS). Cell lysis was performed using 




CA) containing a cocktail of protease inhibitors (Santa 
Cruz  Biotechnology,  Santa  Cruz,  CA).  Protein  con-
centrations in the cytoplasmic extracts were obtained 
using BCA protein assay kit (Pierce, Rockford, IL). For 
immunoprecipitation, 300 μg of cytoplasmic extracts 
was incubated with anti-PI3K at 4°C on an end-to end 
rotator, centrifuged at 10,000x g for 10 min, protein 
A/G beads were added, the mixture was rotated for 3 
hours at 4°C and the immunocomplexes were washed 
three times with lysis buffer. Sodium dodecyl sulfate 
(SDS) sample buffer was added to the beads, and the 
beads were incubated at 95°C for 5 minutes. The su-
pernatant was then separated by electrophoresis and 
transferred to a nitrocellulose membrane. The mem-
brane  was  blocked  with  5%  nonfat  dry  milk  in 
PBS/Tween 20 (0.05%) followed by incubation with 
an  anti-PI3K  antibody  (1:1000  in  10%  milk/PBS-T). 
Visualization  of  the  bound  primary  antibody  was 
done  by  probing  with  horseradish  peroxi-
dase-conjugated  secondary  antibodies  (1:1000)  and 
that  signal  was  revealed  by  exposure  to  a  chromo-
genic detection reagent. 
Visualization and quantification of autophagic 
vacuoles in MCF-7 cells 
MCF-7  cells  were  treated  with  0-  50  μM  of 
ceramide  for  24  hours  visualization  of  autophagic 
vacuoles, MCF-7 breast cancer cells were grown on 
coverslips for 24 hours labeled with 0.05 mM mono-
dansylcadaverine  (MDC)  in  PBS  at  37°C  for  10 
minutes.  After  incubation,  cells  were  washed  four 
times with PBS and analyzed using an Axiovert 405M, 
inverted microscope equipped with epi-fluorescence. 
For  quantification  of  autophagic  vacuoles  in  cells, 
cells were plated in 96-well plates and treated with 
ceramide followed by incubation with 0.05 mM MDC 
in PBS at 37°C for 10 minutes (16). After incubation, 
cells were washed with PBS four times and collected 
in  10  mM  Tris-HCl  (pH  8  containing  0.1%  Triton 
X-100). Intracellular MDC was measured at 380/520 
nm using Perkin Elmer LS 50B spectro- fluorometer. 
DNA fluorescence was measured by adding ethidium 
bromide to a final concentration of 0.2 μM and meas-
ured at 530/590 nm using Perkin Elmer LS 50B spec-
trofluorometer.  
Cell migration assay 
Cell  migration  assays  were  performed  in  a 
96-well  disposable  chamber (Chemicon  Quantitative 
Cell Migration QCMTM, catalog number ECM 510) as 
per the manufacturer’s instructions. MCF-7 (1.0 x 106 
cells) in 100 μl of media was added to the membrane. 
The wells of the feeder tray were loaded with 150 μl of 
media containing 0.1% BSA (negative control) or 0.1% 
fetal  bovine  serum  and  10  ng/ml  VEGF  as 
chemo-attractants.  Plates  were  incubated  in  a  cell 
culture incubator at 5% CO2, 37
C for 6 hours. MCF-7 
cells  pretreated  with  10-50  μM  ceramide  or  DMSO 
(vehicle) for 24 hours were added to each well. At the 
end of a 6 hour incubation period, the cells were dis-
lodged from the underside of the membrane using cell 
detachment buffer and  split  with lysis  buffer  along 
with the dye and 150 μl of the mixture was transferred 
to a 96-well plate suitable for fluorescence measure-
ments. The plates were read at 480nm/520 nm using 
Perkin Elmer LS 50B spectrofluorometer. Results were 
normalized to one hundred percent migration of con-
trol MCF-7 cells and reported as relative migration. 
ELISA assays for VEGF 
MCF-7 (2 x 106 cells per well) cells were plated in 
6-well dishes and treated with 0-50 μM of ceramide 
for  24  hours.  After  the  treatment,  the  supernatants 
were  collected  for  the  quantification  of  VEGF  and 
cathepsin  D.  VEGF  levels  in  the  supernatants  were 
determined using a commercial sandwich ELISA kit 
(Chemicon, Temecula, CA).  
In Vitro angiogenesis and tube formation Assay 
In vitro angiogenesis assays were performed us-
ing a commercially available kit from Chemicon Inc. 
(catalog ECM 625, Chemicon,  Temecula,  CA). After 
preparing the gel matrix, as per the manufacturer’s 
instructions, and allowing it to solidify, HUVEC (1.0 x 
104 cells in 50 μl) were seeded onto the surface of the 
polymerized EC Matrix in the presence of 10 ng/ml of 
VEGF alone or VEGF and 0-50 μM of ceramide dis-
solved  in  DMSO.  The  plates  were  incubated  at  5% 
CO2, 37oC for 6 hours. Tube formation was inspected 
and images were photographed using a Nikon color 
camera  mounted  to  Leitz  phase  contrast,  inverted 
microscope (10X magnification). 
The embryonic chick chorioallantoic membrane 
(CAM) assay 
Fertilized  chicken  eggs  were  obtained  from 
Spafas (Norwich, CT). The shells were cleaned with 
70% ethanol. The eggs were then incubated at 37°C for 
three days. After incubation, the eggs were cleaned 
with 70% ethanol, carefully cracked, and the embryos 
were carefully explanted into sterile Petri dishes and 
incubated  for  two  days  at  37°C  and  3%  CO2.  Fif-
ty-micromolar  ceramide  (dissolved  in  DMSO)  was 
applied to a nylon mesh (Tetko, #3-300/50, 4 x 4 mm) 
and subsequently freeze dried. The mesh was placed 
on an outer third of the CAM and the Petri dish con-
taining the CAM was returned to the incubator. Im-
ages  of  both  control  and  exposed  CAMs  were  ac-
quired  digitally  24  hours  after  the  onset  of  the 




sels was analyzed at later times. The total length of the 
vessels in each region was measured using the NIH 
Image 1.63 program as described by others (17).  
Zebrafish embryo collection and ceramide expo-
sures 
Embryos  were  generated  by  natural  pair-wise 
mating (18). For each mating, 4-5 pairs were set up 
and an average of 100-150 embryos per pair was gen-
erated. Embryos were maintained in embryo medium 
(0.2  g/l  of  Instant  Ocean  Salt  in  distilled  water)  at 
27-28C for approximately 10 hour before sorting for 
viability, using both morphology and developmental 
stage as criteria. Embryos were then dechorionated by 
enzymatic digestion with 1.4 mg/ml protease (Sigma, 
St.  Louis,  Missouri,  USA)  for  7-8  minutes  at  room 
temperature. The dechorionated embryos were then 
washed at least ten times in embryo medium. They 
were then exposed to medium containing 0.2- 0.8% 
DMSO and ceramide (100-400 µM) beginning at 10-14 
hours post fertilization (hpf), the period of develop-
ment before the vicinity of angiogenic vessels express 
VEGF (~19 hpf). After ceramide addition, the embryos 
were maintained in individual petri dishes at 27-28C, 
until  48-72  hpf.  Individual  embryos  were  visually 
inspected  for  viability,  gross  morphological  defects, 
and alterations in heart rate and circulation. Circula-
tion  was  assayed  by  visually  comparing  the  move-
ment of blood cells in treated and control embryos to 
assess the relative blood flow rate. The embryos were 
visually inspected every six hours following ceramide 
treatment until 36 hpf. Later, the embryos were mon-
itored every hour until 56 hpf to assess the onset of 
intersegmental blood vessels (ISBV) blood circulation 
which usually starts between 36-48 hpf and is com-
pleted  by 56  hpf  (12).  Each  individual  embryo  was 
videotaped using a CCD camera mounted to a Zeiss 
dissecting microscope (Thornwood, NY). 
Morphological analysis: vascular development 
In living embryos,  intersegmental blood vessel 
(ISBV)  patterning  was  observed  utilizing  the trans-
genic line of zebrafish Tg(fli1:EGFP)y1 referred to as 
Fli-1 from here onward. Fli-1 is an endothelial marker 
and  GFP attached to the  Fli-1 promoter aids in the 
observation  of  vasculature  structure  formation  of 
zebrafish  during  embryogenesis.  The Fli-1 line  was 
obtained from the Laboratory of Brant Weinstein at 
the National Institute of Health, USA. Images of GFP 
positive, Fli-1 embryos were acquired digitally with 
an  ORCA-ER  camera  mounted  to  a  Zeiss  inverted 
microscope  with  epi-fluorescence  capabilities.  The 
GFP filter cube on the microscope was used to acquire 
the GFP fluorescent signal.  
Digital  images  of  living  embryonic  zebrafish 
from the region caudal to the anal fin were also ac-
quired with bright-field DIC optics with a 40x objec-
tive. We imaged 8-10 segments in each analyzed fish. 
In DMSO control 48hpf embryos, blood flow was eas-
ily detected in the both intersegmental veins and ar-
teries. DMSO control and ceramide-exposed embryos 
were imaged and scored to determine the presence of 
blood  flow  in  each  of  those  imaged  segments.  In 
DMSO control embryos, blood flow was evident in all 
segments  analyzed  with  DIC  optics.  Segments  in 
ceramide-exposed  embryos  often  completely  lacked 
blood flow. Those vessels were documented and kept 
track of in their corresponding images. Those blood 
vessels  lacking  blood flow  were  then  analyzed  and 
their diameters quantified separately from the blood 
vessels  that  exhibited  blood  flow.  Quantification  of 
vessel  diameter  was  performed  using  the  analysis 
software provided in Axiovision 4.6. 
Morphological analysis: motoneuron development 
For examination of CaP motoneurons in living 
embryos exposed to ceramide, embryos of the NBT 
line  were  used.  In  30-36  hpf  embryos  of  the 
Tg(NBT:MAPT-GFP)zc1 transgenic line, GFP can eas-
ily be detected in CaP motoneuron axons. The NBT 
line was kindly provided by Dr. Chi Bin Chien (Uni-
versity  of  Utah  Medical School,  Salt  Lake  City).  To 
examine  MiP  axon  morphology,  whole  mount  im-
munohistochemistry was performed using a modified 
version  of  our  previously  published  immunohisto-
chemistry  protocol  (19,  20).  Embryos  processed  for 
immunohistochemistry  were  first  fixed  in  4%  para-
formaldehyde overnight at 4oC and then stored in PBS 
or phosphate buffered saline with Tween 20 (PBST). 
After this, the embryos were incubated in a primary 
antibody  overnight  at  4oC.  The  primary  antibody 
znp1, which labels primary motoneuron axons, was 
used  at  a  dilution  of  1:250.  The  following  day,  the 
embryos were washed for 60 min in PBS buffer and 
then incubated in a fluorescent secondary antibody, 
Alexa 546 (1:1000 dilution) for 90 minutes. Embryos 
were then rinsed with PBST for another 60 min and 
prepared for image analysis. Images of stained em-
bryos  were  acquired  digitally  with  an  ORCA-ER 
camera mounted to a Zeiss inverted microscope with 
epi-fluorescence capabilities. The 543 nm filter cube 
on the microscope was used to acquire the rhodamine 
fluorescent signal.  
Acridine orange staining in zebrafish 
Living embryos (30-36 hpf) were exposed to Ac-
ridine Orange (AO) for 60 minutes at room tempera-
ture. A working concentration of 5 µg/ml was used 
with the AO being made in embryo medium. After 




several times in embryo medium and then transferred 
to petri dishes containing MS222. Once anesthetized, 
the embryos were mounted on a slide and images of 
dying cells in embryos were acquired digitally with 
an  ORCA-ER  camera  mounted  to  a  Zeiss  inverted 
microscope with epi-fluorescence capabilities. The 543 
nm filter cube on the microscope was used to acquire 
the rhodamine fluorescent signal.  
Statistical Analysis 
All values presented in bar graphs are means ± 
standard error of the means (SEM). Kruskall-Wallis 
analysis of variance was performed to test for signifi-
cance between control values and experimental val-
ues. In some instances where appropriate, a Student 
T-test was used to test for statistical significance. Sig-
nificance was assigned if the p value was < 0.05. In all 
examples denoted by *, p value is < 0.01 when com-
paring experimental values to control values. 
Results 
Ceramide induced autophagy, a specific type of cell 
death 
MCF-7 cells were plated for 24 hours and evalu-
ated for viability in the presence of various concen-
trations of ceramide. Ceramide inhibited the viability 
of  MCF-7  breast  cancer  cells  in  a  dose  dependent 
manner. At 12.5 M or less, ceramide did not affect 
the viability and proliferation of MCF-7 cells. How-
ever, at concentrations equal to or above 50 M, the 
viability of MCF-7 cells was inhibited by roughly 75 
%. (Figure 1A and 1B).  
 
 
Figure 1. Ceramide exposure affects cell growth and proliferation in vitro. (A) Control MCF-7 cell-line and 25-50 M 
ceramide-exposed MCF-7 cell-lines treated for 24 hours. (B) Cell viability quantification illustrating the effect of 
ceramide on cells of the MCF-7 cell-line treated for 24 hours. Ceramide exposure altered the viability of the MCF-7 
cell-lines in a concentration dependent manner. Note that at 12.5 M ceramide, no significant cell death is induced 
by ceramide (black arrow). (C) Cathepsin D levels in MCF-7 cells exposed to ceramide at a concentration of 50 µM for 
24 hours. Results are represented as Cathepsin D concentration (ng/mL). Data are from three experiments conducted 
in triplicates (* p < 0.001). (D) Westernblot of PI3K protein expression in MCF-7 cells exposed to 25 M and 50 M 
ceramide for 24 hours. (E) Visualization of monodansylcadaverine (MDC) indicative of autophagic vacuole formation 





 At this concentration, markers of cell death were 
significantly up-regulated.  Ceramides are known  to 
bind and activate cathepsin D followed by the auto-
catalytic proteolysis of the 52 kDa isoform to the en-
zymatically active 48/32 kDa isoforms of the enzyme 
(21-23).  Cathepsin D has been implicated in the re-
lease of cytochrome C, followed by the activation of 
caspases  and  ultimately  the  induction  of  cell  death 
(24). The level of cathepsin D was increased following 
incubation of MCF-7 cells with 50 M ceramide (Fig-
ure 1C). 
Further analysis revealed that the cell death re-
sulting  upon  ceramide  exposure  in  MC-7  cells  was 
autophagy. Autophagy is a specific form of cell death 
characterized  the  accumulation  of  monodansylca-
daverine  (MDC)  in  mature  autophagic  vacuoles. 
Moreover, several signaling pathways, including tar-
gets  of  rapamycin  (mTOR),  phosphatidylinositol 
3-kinase-I (PI3K-I)/PKB, GTPases, along with calcium 
and protein synthesis have been shown to play im-
portant roles in regulating autophagy. The PI3K fam-
ily is comprised of three main classes: I, II, and III and 
all  these  mediate  cellular processes  such  as  growth 
and  survival,  entrance  into  the  cell  cycle, adhesion, 
and migration (25). Ceramides inhibit class III PI3K 
signaling  pathways  and  stimulate  beclin  I  protein 
which mediate autophagy (6). Ceramides are known 
to  stimulate  autophagy  by  interfering  with  class  I 
PI3K signaling pathways. Moreover ceramide levels 
are present at lower levels in cancer cells than normal 
cells, suggesting that ceramide may be an important 
factor in the regulation of autophagy (26). The ability 
of ceramide to down regulate the expression of PI3K 
was  confirmed  by  western  blot.  MCF-7  controls 
showed  abundant  level  of  PI3K  protein  expression 
whereas  MCF-7  cells  incubated  with  50  μM  of 
ceramide exhibited a complete reduction in PI3K ex-
pression (Figure 1D). 
 The  accumulation  of  monodansylcadaverine 
(MDC)  in  mature  autophagic  vacuoles  such  as  au-
tophagolysosomes,  but  not  in  the  early  endosomal 
compartment is a reliable marker of autophagy (27). 
Consequently,  we  utilized  monodansylcadaverine 
staining to detect the presence of autophagic vacuoles 
and autolysosomes in control and ceramide exposed 
MCF-7 cells (16, 27). In MCF-7 cells treated with 50 
μM of C6 ceramide for 24 hours, the accumulation of 
monodansylcadaverine was very evident whereas in 
untreated MCF-7 tumor cells, monodansylcadaverine 
was  not  detected  (Figure  1E).  The  fact  that  no  au-
tophagic  vacuoles  were  observed  in  MCF-7  control 
cells  indicates  that  ceramide  exposure  at  50  μM 
caused cell death by autophagy in the exposed MCF-7 
cells (16).  
Ceramide inhibits migration of MC7-cells in vitro 
 Ceramide at concentrations of 12.5 and 25 μM, 
inhibited  the  MCF-7  cells  motility  in  presence  of 
VEGF that served as a chemoattractants (Figure 2A). 
Endothelial  cells  migrate  by  chemotaxis  caused  by 
angiogenesis-inducing growth factor such as VEGF. 
Inhibition of VEGF receptors reduces the migration of 
endothelial cells towards the chemo-attractant VEGF. 
Incubation  of  MCF-7  cells  with  the  ceramide  (0-50 
μM)  inhibited  VEGF  release  into  the  medium  in  a 
concentration-dependent  manner  (Figure  2B).  The 
significant  difference  between  the  control  and 
ceramide-treated  cells  may  explain  the  reduced  mi-
gration  of  breast  cancer  cells  towards  VEGF  as 
chemo-attractant.  
Ceramide inhibits tube formation by endothelial 
cells 
 In the MCF-7 cell lines, ceramide exposure re-
sulted in autophagy at high concentrations. However, 
at lower concentrations that did not result insubstan-
tial  cell  death,  ceramide  exposure  significantly  re-
duced  cell  migration.  Because  of  this,  we  hypothe-
sized that ceramide exposure could potentially inhibit 
tube formation in endothelial cells which would sug-
gest that ceramide may ultimately be able to alter an-
giogenesis via a mechanism not coupled to cell death. 
To  test  this,  the  effect  of  ceramide  exposure  on 
HUVEC was investigated.  
On  a  synthetic  basement  membrane  matrix, 
human umbilical vein endothelial cells are capable of 
morphological  differentiation into  an  extensive  net-
work of capillary-like structures composed of highly 
organized three-dimensional cords. The alignment of 
endothelial cells in capillary-like structures is a func-
tional  trait  that  is  typical  of  angiogenesis.  In  the 
presence of 10 ng/ml of VEGF, human umbilical vein 
endothelial cells plated on the EC matrix aligned and 
formed capillary-like structures within 6 hours (Fig-
ure 2C). Exposing HUVEC to 25 µM ceramide inhib-
ited tube formation within 6 hours as revealed by the 
capillary-like network within the ECmatrix typical for 
HUVEC being disrupted (Figure 2C). 
Thus, in all of these in vitro assays, ceramide is 
having  an  apparent  dual  effect  on  cell  biology.  At 
concentrations  ranging  between  12.5  and  25  μM 
ceramide,  cell  migration  and  tube  formation  were 
affected  by  ceramide  exposure.  Importantly,  VEGF 
was also significantly reduced by exposure to 12.5 μM 
ceramide. Remembering that ceramide did not cause a 
significant decrease in cell viability at this concentra-
tion (Figure 1B), it is likely that the inhibition of an-




ready known effect on cell death, at least in the in vitro 
assays utilized in this study. 
At 50 μM, the induction of autophagy resulted 
upon ceramide exposure. Thus, the dose responsive-
ness of the differing phenotypes revealed a dual mode 
of action for ceramide. Exposures at low concentra-
tions  inhibited  tube  formation  and  migration  and 
exposure to high concentrations of ceramide resulted 
in autophagy. 
 
Ceramide inhibits blood vessel growth in vivo 
Our in vitro data to this point strongly suggested 
that ceramide may directly influence angiogenesis. To 
determine  if  ceramide  exposure  influenced  angio-
genesis in vivo, the consequences of ceramide expo-
sure  on angiogenesis  in  two  vertebrate  models,  the 
embryonic  chick  chorioallantoic  membrane  (CAM 
(28)), and the zebrafish model were investigated. In 
the in vivo CAM assay, 50 μM ceramide caused a sig-
nificant  reduction  of  embryonic  angiogenesis  by  as 
much as 40% within 24 hours. DMSO at 0.1% as sol-
vent  for  ceramide  had  no  effect  on  vessel  growth 
(Figure  3).  Ceramide-exposed  chorioallantoic  mem-
branes  exhibited  diminished  blood  vessel  develop-
ment and the blood vessels were also retracted away 
from the exposed region of embryo. Ceramide expo-
sures  longer  than  24  hours  were  deleterious  to  the 




Figure 2. In vitro assays of tumorogenesis and tube formation, consequences of ceramide exposure. (A) Ceramide 
exposure inhibits cell migration. Results are expressed as percent of control (vehicle-treated cells) and the means of 
triplicate determinations ± SE. Data are from one experiment and are representative of three replicated experiments 
(*p < 0.001). (B) Effect of ceramide exposure (5 µM - 50 µM) on VEGF expression in MCF-7 cells treated for 24 hours. 
Results are represented as a VEGF concentration (pg/mL) after normalization based on cell viability. Data are from 
three experiments conducted in triplicates (p < 0.001). (C) HUVEC containing 10 ng/ml of VEGF were plated on a 
Matrigel and they typically aligned forming cord-like structure. The asterisks in the 25 µM example denote a region 





Figure 3. Effect of ceramide exposure on embryonic angiogenesis in the chick chorioallantoic membrane (CAM) assay. 
(A) Ceramide (50 μM) was applied to the surface of the embryonic chick CAM for 24 hours. The blood vessels are easily 
detected in the CAM at 0 hour prior to the ceramide exposure. The black box denotes a region of interest to allow for 
comparisons between the image taken at 0 hour and the one taken 24 hours later. (B) The effect of ceramide ex-
posure on blood vessel length during a 24 hours period of development was quantified and presented in bar graph 
form (* p < 0.02). Scale bar = 1.0 mm.  
 
 
With the effect on angiogenesis in the CAM as-
say  established,  we  then  set  out  to  determine  the 
consequences of ceramide exposure in zebrafish em-
bryos. There are numerous reasons for doing so, but 
the  primary  driving  force  was  the  fact  that  other 
groups had documented a link between angiogenesis 
and  nervous  system  development  (15,  29,  30).  If 
ceramide  exposure  was  indeed  affecting  signaling 
cascades  involved  with  angiogenesis,  we  hypothe-
sized that ceramide may also have an effect on nerv-
ous  system  development,  in  this  case,  axonal 
path-finding  of  spinal  motoneurons.  Since,  the 
zebrafish model is well-established model for study-
ing  many  aspects  of  development,  extending  our 
studies to a system where we could easily assay blood 
vessel and neuronal development along with apopto-
sis was an important next step in this study. In the 
CAM  assay,  we  could  not  determine  if  the  an-
ti-angiogenic  effects  of  ceramide  were  related  to 
ceremide’s established ability to induce autophagy. In 
zebrafish  embryos,  cell  death  including  autophagy 
can be analyzed with a wide array of cell biological 
techniques  (31,  32).  Thus,  the  utilization  of  the 
zebrafish model would let us determine the mecha-
nism by which ceramide inhibits angiogenesis in vivo; 
either by directly effecting angiogenic pathways or by 
initiating autophagy which would then result in in-
hibited angiogenesis. 
Toxicology of ceramide exposure in zebrafish: ef-
fects on gross morphology and angiogenesis  
The  ability  of  zebrafish  to  tolerate  the  solvent 
DMSO, which was used as a carrier for ceramide, was 
evaluated  and  no  morphological  changes  were  ob-
served at 1% DMSO. Based on this solubility criteria 
and an effective concentration of ceramide, a working 
waterborne  concentration  of  0.2  -  0.8%  DMSO  as  a 
carrier  solvent  was  established.  All  subsequent  ex-
periments were conducted with ceramide concentra-
tions ranging from 100 M to 400 M. The first ob-
servable phenotypes were detected at a waterborne 
exposure concentration of 100 M. 
Ceramide exposure (14 - 48 hpf) had no effect on 
the gross morphology of the zebrafish embryos (Fig-
ure 4A). However, exposure caused a complete loss 
of,  or  disrupted  blood  flow  in  70%  of  the  embryos 
examined (n= 117/166, embryos that were individu-
ally videotaped, Figure 4C, 4D-left panel). This dis-
rupted  blood  flow  was  specific  for  blood  flowing 
through  the  intersegmental  veins  (ISVs)  and  in-
tersegmental arteries (ISAs), collectively referred to as 
intersegmental blood vessels (ISBVs, Figure 4B). The-
se vessels are located in the mid-trunk region of every 
segment in zebrafish embryos (Figure 4B, Figure 4C). 
In contrast to this, blood flow was easily detected in 
the dorsal aorta and PCV in the ventral region of em-
bryos adjacent to the yolk sac. 






Figure 4. Ceramide effects on zebrafish morphology and blood flow. (A) Composite images of head, mid-trunk, and 
tail regions of a DMSO-exposed (control) 48 hpf embryo and a composite image of head, mid-trunk and tail regions of 
48 hpf embryo exposed to ceramide. The heart in each is denoted by the black arrowhead. (B) Blood vessel devel-
opment in zebrafish embryos. At the top is a schematic diagram of the zebrafish circulatory system in the trunk region 
illustrating key structures. (ISA: Intersegmental artery; ISV: Intersegmental vein; DLAV: dorsal longitudinal anas-
tomotic vessel). Blood flows caudally (to the right) via the dorsal aorta (DA), and returns rostrally (to the left) via post 
cardinal vein (PCV). At the bottom is a brightfield image of blood vessels in a 48 hpf embryo. Dashed lines denote the 
vessels. (C) Intersegmental blood vessel (ISBV) diameter in the mid-trunk region is altered in zebrafish embryos 
exposed to ceramide. Top; DMSO- exposed embryo at 48 hpf. Bottom; ceramide-exposed embryo at 48 hpf. White 
arrows in both images denote ISBVs. Black arrows point to individual blood cells. D. Quantification revealed that 
ceramide exposure altered blood flow in 69% of the embryos examined. Heart rates were also measured and found to 
be similar in both cases. Lastly, in ceramide exposed embryos, intersegmental blood vessels (ISBVs) that lacked blood 
flow were significantly thinner in diameter than blood vessels in DMSO control embryos (* p < 0.01). Scale bars = 500 





Ceramide exposure had no significant effect on 
heart rates in zebrafish embryos analyzed between 40 
and  48  hpf  (Figure  4D-middle  panel).  At  40hpf, 
ceramide-exposed embryos had an average heart rate 
of 150.3 beats per minute (n=18) compared 155 beats 
per minute in DMSO controls (n=14). By 48 hpf, the 
heart rates of DSMSO control embryos averaged 165. 
7  beats  per  minute  whereas  the  heart  rates  in 
ceramide-exposed  embryos  was 170.6 beats  per  mi-
nute (n=14, 18 respectively) and this difference was 
not  statistically  significant  (p  =  0.076).  Those  same 
embryos were then analyzed to see if they had dis-
rupted blood flow through the ISBVs. In a majority of 
cases, ceramide-exposed embryos lacked blood flow 
in the ISBVs. The loss of blood flow through the ISBVs 
coupled with normal heart rates in ceramide-exposed 
embryos suggested that the morphology of the blood 
vessels  was  altered  in  those  ceramide-exposed  em-
bryos.  
Analysis of the ISBV diameters from those em-
bryos in which heart rate information was gathered 
revealed  that  some,  but  not  all  ISBVs  were  signifi-
cantly  thinner  in  diameter  in  the  ceramide-exposed 
embryos (Figure 4C, Figure 4D-right panel). Between 
42 hpf and 48 hpf, blood flow through the ISBVs was 
easily  detected  in  control  DMSO  exposed  embryos. 
The region analyzed was caudal to anal fin at the tip 
of the yolk sac extension. As the embryo ages, blood 
flow can be detected in more anterior ISBVs. We an-
alyzed  a  seven-eight  segment  region  caudal  to  the 
anal fin in 48 hpf control and ceramide-exposed em-
bryos. In all DMSO control embryos analyzed in this 
manner  (n=14),  robust  blood  flow  was  detected  in 
almost  all  the  ISBVs  analyzed  (111/112).  In  the 
ceramide  treated  embryos,  normal  blood  flow  was 
evident in 66% of the ISBVs analyzed (99/149). The 
ISBVs  exhibiting  no  blood  flow  were  significantly 
thinner in diameter (4.1 ± 0.12 microns, n=50) than the 
ISBVs of ceramide treated embryos that had robust 
blood flow through them (8.66 ± 0.18 microns, n=99, 
Figure 4D). 
In  all  of  the  experiments  presented  thus  far, 
zebrafish embryos were mobile and quite responsive 
to touch. Except for the lack of blood flow through the 
ISBVs,  no  other  abnormal  phenotypic  effects  were 
detected with light microscopy. There were also no 
observable morphological changes in DMSO-exposed 
control embryos. Removal of ceramide and the return 
of embryos to normal embryo media at 56 hpf failed 
to restore the blood flow pattern back to normal, as 
some of the ISBVs still lacked blood flowing through 
them even when assayed as late as 72 hpf.  
Ceramide effects on ISBV patterning 
The circulatory system in zebrafish has been ex-
tensively studied and the mechanisms of angiogenesis 
have  been  well  characterized  by  others  (12,  33).  A 
developmental  timeline  highlighting  key  molecular 
events during angiogenesis drawn from the literature 
is illustrated in Figure 5A.  
The results presented to this point indicate that 
the  reduced  blood  flow  through  ISBVs  in 
ceramide-exposed embryos was due to altered blood 
vessel development, primarily due to thinning of the 
vessels and/or altered patterning of the developing 
vasculature. The intersegmental blood vessels (ISBVs) 
in  zebrafish  are  arranged  in  an  extremely  regular 
pattern.  In  the  medial-lateral  plane,  the  ISBVs  run 
between  the  notochord  and  somite  ventrally,  while 
they are restricted between the neural tube and somite 
boundaries dorsally (12). ISBVs, like motoneuron ax-
ons, exhibit regular patterns of organization and this 
pattern is maintained along both the anterior posteri-
or axis as well as the dorsal ventral axis of the embryo. 
This pattern, which is established early in develop-
ment,  is  highlighted  in  figure  4B.  The  ISBVs  are 
evenly  spaced  from  segment  to  segment  and  they 
have a characteristic “S” profile as they extend dorsal 
to  ventral  (Figure  4B-bottom-panel,  Figure  5E).  The 
ISBVs connect ventrally to either dorsal aorta or pos-
terior  cardinal  vein,  respectively  and  run  dorsally 
between and adjacent to the notochord, neural tube 
and the somites (34). The spacing between ventral and 
dorsal aspects of individual ISBVs is consistent along 
the anterior posterior axis with no obvious irregulari-
ties. Simultaneously, there is a similar patterning of 
spinal motoneurons being established during devel-
opment. Axons and blood vessels therefore may make 
use of common signaling pathways (Figure 5A) often 
complementing  each  other  utilizing  guidance  cues 
which repel or attract developing blood vessels and 
axons (30). 
To determine if blood vessel development was 
altered by ceramide exposure at developmental time 
points  preceding  the  onset  of  blood  flow,  vessel 
morphology was investigated in embryos expressing 
GFP in their vasculature system. The morphology of 
the  GFP-positive  ISBVs  in  ceramide-exposed  Fli-1 
embryos exhibited abnormal ISBV formation as early 
as 30 hpf (Figure 5B). There were two major pheno-
types observed.  
 





Figure 5. Ceramide inhibits angiogenesis in zebrafish embryos. (A) Developmental timeline of gene expression for 
particular genes implicated in both angiogenesis and primary motoneuron development in embryonic zebrafish. (B) 
Left; GFP positive blood vessels in 30 hpf Fli-1 control embryos. Doral ventral projecting ISBVs develop in a patterned 
manner and are evenly spaced throughout the length of the embryo. Middle; GFP positive blood vessels in Fli-1 
embryos reveal patterning misguidance in embryos exposed to ceramide (white arrowheads). All photomicrographs 
were obtained from the same 3 segments in the mid trunk region. (C) Higher magnification view of middle panel in B 
is shown at the right. At the left is DMSO exposed embryo. The DLAV in the ceramide-exposed embryo has not 
completely formed and has a disorganized appearance. (D) Acridine Orange (AO) staining in 30 hpf control and 
ceramide exposed embryos. (E) Ceramide exposure in 48 hpf Fli-1 embryos results in differing abnormal phenotypes 
(white arrowheads). ISBVs of a 48 hpf DMSO-exposed (control) zebrafish embryo are shown at the far left. (F) DLAV 
formation was also effected in 48 hpf ceramide-exposed embryos. Left; DLAV in a 48hpf, DMSO exposed control 
embryo is denoted by the white arrows. Right; DLAV of ceramide exposed zebrafish embryo. Scale bars in all panels 
= 20 µm. 
 
Consistent  with  observations  made  with  DIC 
microscopy, these young embryos exhibited thinner 
ISBVs.  Moreover,  some  vessels  did  not  exhibit  the 
characteristic  “S”  profile  typical  of  normal  vessels; 
instead they projected in a straight line from dorsal to 
ventral  (Figure  5B-middle  panel)  We  also  detected 
errors in DLAV formation analogous to what we ob-




viously presented (Figure 5B-right panel, Figure 5C) 
The  DLAVs  did  not  form  precise  organized  tubes. 
Instead, they appeared as a tangled meshwork of GFP 
positive endothelial cells. 
We  analyzed  cermaide-exposed  zebrafish  em-
bryos to test for the distinct possibility that apoptosis 
was  being  up-regulated  by  ceramide  in  vivo.  Cell 
death  in  ceramide-exposed  and  DMSO  control  em-
bryos was assessed with Acridine Orange staining in 
living embryos (Figure 5D). Acridine Orange is a vital 
dye  that  has  been  used  in  zebrafish  to  detect  cells 
undergoing cell death (31, 32). We performed Acri-
dine Orange staining on both ceramide-exposed and 
DMSO control embryos (30-36 hpf, n=32 and 28 re-
spectively). We chose this developmental time-point 
because  we  first  detected  changes  in  blood  vessel 
morphology  at  30  hpf.  Somewhat  surprisingly, 
ceramide  did  not  up-regulate  apoptosis  in  the 
zebrafish  assay  when  compared  to  DMSO-exposed 
embryos.  Thus,  in  the  in  vivo  zebarfish  assay, 
ceramide exposure results in inhibition of angiogene-
sis but not the initiation of cell death. 
Analysis  of  48  hpf  Fli-1  embryos  further  vali-
dated the results obtained with DIC microscopy for 48 
hpf, ceramide-exposed embryos. Some, but not all of 
the ISBVs as well as DLAVs were thinner in diameter 
in  ceramide-exposed  Fli-1  embryos  compared  to 
DMSO-exposed  embryos  (Figure  5E,  Figure 
5F-middle  image).  In  some  cases,  ISBVs  appeared 
stalled  or  stunted  in  development  (Figure  5E,  right 
image)  resulting  in  incomplete  vessel  formation. 
These stunted vessels appeared to just stop develop-
ing  and  did  not  form  the  appropriate  connections 
with the DLAVs. 
Effects of ceramide on primary motoneurons de-
velopment in zebrafish 
We first conducted motoneuron axon studies in 
NBT transgenic zebrafish embryos because their GFP 
positive, motoneuron axons are easily detectable early 
on  in  development.  These  experiments  were  con-
ducted because it has been documented that axonal 
trajectories during CNS development require some of 
the same guidance cues needed for the patterning of 
the  blood  vessel  formation  (29,  30,  35-38).  Since 
ceramide  exposure  had  such  a  profound  effect  on 
blood vessel development in zebrafish embryos, we 
hypothesized that the ceramide exposure would alter 
motoneuron axonal development.  
Three primary motoneurons are present in the 
developing ventral spinal cords of zebrafish embryos 
and have been individually identified as the caudal 
primary  (CaP),  middle  primary  (MiP),  and  rostral 
primary (RoP) neurons (39, 40). A schematic diagram 
of two of these three primary motoneurons, CaP and 
MiP is illustrated in Figure 6A. The axons of the pri-
mary motoneurons have been shown to follow spe-
cific trajectories to the periphery (41, 42). Like blood 
vessel  development  in  zebrafish,  axonal  trajectories 
exhibit a very organized pattern of development. As 
shown in figure 6A, MiP axons innervating the dorsal 
periphery  are  evenly  spaced  from  segment  to  seg-
ment. By 30hpf, the axons have extended to the most 
distal portion of the periphery. CaP axons follow a 
similar  pattern  of  organization,  but  innervate  the 
ventral  musculature.  Both  MiP and  CaP  axons lack 
branching early in development. These primary mo-
toneurons in zebrafish spinal cord develop at 15 hpf 
and begin extending axons into the periphery at ap-
proximately 17 hpf. This is right at the time that VEGF 
expression first begins to appear in the trunk region of 
the zebrafish. 
Zebrafish  embryos  exposed  to  ceramide  dis-
played abnormal primary motoneuron axonal trajec-
tories in all the NBT embryos examined (n=13, 30 hpf 
embryos). Three abnormal phenotypes were evident. 
CaP axons (see figure 6A for schematic of these axons) 
were  stunted  at  the  region  close  to  the  horizontal 
myoseptum in the ventral somite region (Figure 6B). 
Instead  of  extending  into  the  distal  periphery,  the 
axons appeared to stop developing prior to entering 
the distal periphery. This phenotype was very similar 
to the stunted blood vessel development caused by 
ceramide exposure shown in figure 5E. CaP axons in 
ceramide-exposed embryos, in some instances, made 
straight-line  trajectories  into  the  periphery  just  like 
some  of  the  ISBVs  in  ceramide-exposed  embryos. 
Lastly, CaP axons in ceramide-exposed embryos ex-
hibited ectopic branching. This was not seen in control 
embryos (Figure 6B).  
The effect of ceramide exposure on MiP axonal 
trajectories in the NBT transgenic embryos was diffi-
cult to assess due to high background of the expressed 
GFP in the dorsal region of spinal cord. Therefore, we 
analyzed the effect of ceramide exposure on MiP ax-
ons  in  wildtype  embryos  by  znp1  immunostaining. 
Znp1 immunostaining also confirmed ceramide effetc 
on the CaP axon phenotypes. CaP axons were stunted 
in development failing to extend to the distal periph-
ery, took straight-line trajectories to the periphery, or 
exhibited  ectopic  branches.  All  of  these  abnormal 
phenotypes  were  easily  detected  with  the  antibody 
znp1 (Figure 6C, n=18 embryos). Ceramide exposure 
also caused MiP motoneuron axons to develop ectopic 
branches (Figure 6D). In some cases, the MiP axons 
appeared  to  traverse  horizontally  along  the  spinal 
cord boundary before extending dorsally, which we 







Figure 6. Ceramide alters primary motoneuron axonal pathfinding in zebrafish embryos. (A) Schematic diagram of a 
lateral view of zebrafish trunk region showing ventral CaP (blue) and dorsal MiP (red) axonal trajectories. Anterior is 
to the left, dorsal is toward the top. (B) Top; image of a 30 hpf DMSO-exposed, NBT transgenic zebrafish. GFP positive 
CaP axons are easily detected as they project to the periphery. Middle; image of a ceramide-exposed, NBT zebrafish. 
White arrows denote stunted axons where the CaP axons split into 2 branches. (C) Top; 30 hpf DMSO control embryo 
stained with the antibody znp1 to detect CaP axon. Middle and Bottom: Ceramide exposure caused a stunt in CaP 
axons (black arrow) and also resulted in CaP axons projecting straight out to the periphery (black arrowhead). (D) 
Left: Magnified image of one segment from a DMSO exposed control embryo in the region of the yolk sac extension. 
Black arrows denote the MiP axon, which innervates the dorsal periphery. Right: Image of 30 hpf, ceramide-exposed 
embryos. The white arrow points to an ectopic branch projecting off the MiP axon. (E) Another example of a 30 hpf 
embryo exposed to ceramide. Bottom: Cartoon depicts the primary motoneuron axonal trajectories for the embryo at 




In  this  study,  we  set  out  to  demonstrate  an-
ti-angiogenic effects of ceramide during development. 
It  has  been  widely  accepted  that  ceramide  causes 
apoptosis in a variety of cells/tissues (43-45). But only 
until very recently, has ceramide been implicated in 
angiogenesis (13, 46, 47). 
Exposure of MCF-7 breast cancer cells to 50 μM 
ceramide for 24 hours caused reductions in cell via-
bility  and  cell  migration.  Ceramide  also  inhibited 
VEGF-induced  HUVEC  tube  formation  in  culture. 
Although the levels of VEGF in culture medium con-
taining  MCF-7  decreased,  cathepsin  D  levels  in-
creased. The results pertaining to cathespin D indicate 
that  ceramide  induces  apoptosis  in  MCF-7  cancer 
cells.  
The fact that the VEGF expression induced by 
cancer cells, which stimulates the endothelial cells to 




exposure suggested that ceramide should be able to 
inhibit endothelial tube formation in culture and ul-
timately affect blood vessel formation in vivo. Both of 
these predictions were validated in this study. In vitro, 
tube formation in endothelial cells, which is the first 
step of sprouting, is inhibited by ceramide exposure at 
concentrations that did not induce apoptosis. These in 
vitro results clearly support the idea that ceramide has 
a  dual  role  and  thus  may  be  powerful  therapy  in 
treating  tumors.  This  study  demonstrates  that 
ceramide at high concentrations can initiate apoptosis 
in  some  cells  including  the  MC7-cells.  Moreover, 
ceramide  exposure  also  inhibits  tube  formation  in 
vitro. Ultimately, this would result with the inhibition 
of tumor progression.  
The results from the embryonic chick CAM assay 
demonstrated  a  significant  reduction  of  vessel  for-
mation within 24 hour of ceramide exposure. To fur-
ther ascertain the effect of ceramide on the developing 
vasculature,  studies  were  then  conducted  in  the 
zebrafish  model  system.  The  zebrafish  vasculature 
system  is  highly  conserved  and  blood  vessel  for-
mation  by  angiogenic  sprouting  requires  the  same 
proteins that are necessary for blood vessel growth in 
mammals  (48,  49).  Our  results  clearly  demonstrate 
that  ceramide  exposure  alters  vasculature  develop-
ment  as  well  as  motoneuron  axonal  pathfinding  in 
zebarfish.  Importantly,  ceramide  exposure  did  not 
induce apoptosis in zebrafish. 
The  angiogenic-patterning  defect  observed  by 
ceramide treatment of zebrafish may be mediated by 
loss of VEGF expression, consistent with our in vitro 
observations. The VEGF downregulation by ceramide 
may also contribute to axonal pathfinding difficulties. 
However,  there  are  several  other  possibilities  by 
which ceramide exposure could regulate axonal path-
finding. First, ceramide may affect axonal patterning 
by interacting with the Shh or BMP pathways (15). 
Secondly, ceramide could potentially regulate endo-
thelial cell development and axonal guidance simul-
taneously,  simply  by  altering  neuropilin  expression 
(13). Lastly, altering VEGF and or VEGF receptor lev-
els could have a profound impact on both vascular 
system and nervous system development. Our in vitro 
studies clearly indicate that ceramide causes a down 
regulation of VEGF. The semaphorins, which are ax-
onal guidance molecules and have been identified in 
zebrafish, bind to the VEGF receptor to facilitate ax-
onal pathfinding. If VEGF receptor levels are reduced, 
the  semaphorins  would  not  likely  be  able  to  exert 
their inhibitory effects during motoneuron develop-
ment  and  axonal  pathfinding.  Future  studies  are 
needed to investigate these intriguing possibilities. 
Our  results  are  in  agreement  with  the  recent 
studies  investigating  the  factors  that  guide  growth 
cone  extensions  that  can  also  regulate  migration  of 
putative angioblasts. VEGF regulates angioblast mi-
gration  and  is  involved  in  axonal  pathfinding  (50). 
Recent studies on glycoproteins such as neuropilin-1 
(NRP1)  and  neuropilin-2  (NRP2)  have  been  impli-
cated in regulating both the semaphorins in neuronal 
guidance  and  vascular  endothelial  growth  factor 
(VEGF) in angiogenesis (51). It may be the case that 
ceramide can also directly regulate the levels of axon-
al guidance factors in zebrafish such as semaphorins, 
ephrins  and  netrins,  and  growth  factors  such  as 
VEGF, EGF, bFGF. All these possibilities require fur-
ther exploration. 
In conclusion, we have demonstrated a dual role 
of  ceramide  in  rendering  the  breast  cancer  cells 
apoptotic as well as inhibiting tumor-induced angio-
genesis. In vivo, ceramide does not appear to induce 
apoptosis,  but  does  affect  angiogenesis.  These find-
ings are novel as they clearly demonstrate a dual role 
for ceramide in potentially containing tumor growth 
not only by directly affecting the tumor proliferation 
via the induction of apoptosis, but also by preventing 
its growth and metastasis by inhibiting the develop-
ment of the vasculature that provides nutrients to the 
growing tumor. This is a very important distinction 
that we argue should not be overlooked. In the con-
text  of  a  developing  tumor,  therapeutic  treatments 
that simply induce apoptosis, may on one hand cease 
the progression of the tumor but may have deleteri-
ous  side  effects  associated  with  inducing  other 
non-cancerous cells into the apoptotic pathway. This 
may not be a good thing. On the other-hand, blood 
vessel development and recruitment of blood vessels 
that  provide  nourishment  to  a  tumor  is  a  develop-
mental phenomenon. This process of angiogenesis, if 
specifically disrupted would ultimately result in the 
starvation of a growing tumor, but not yield delete-
rious side effects. Exposure to ceramides at concen-
trations that did not induce apoptosis would still in-
hibit any angiogenic events and likely nothing else. 
We also predict that ceramide exposure would have 
little effect on an established vasculature system, just 
a developing one, making for a potentially powerful 
cancer therapeutic producing little if any side effects 
in adult organism. 
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